Fricimab demonstrated superior and faster anatomic improvements compared to aflibercept in diabetic macular edema (DME) over 100 weeks, according to a study. It led to greater reductions in central subfield thickness (CST), a higher proportion of eyes achieving absence of intraretinal fluid (IRF), and faster achievement of key anatomic benchmarks.
The trials included 1,891 adults with center-involving DME who were randomized to receive either faricimab every 8 weeks (Q8W), faricimab in a treat-and-extend (T&E) regimen, or aflibercept Q8W over 100 weeks.
Results showed that faricimab led to greater CST reductions compared to aflibercept throughout the study. At weeks 92-100, a higher proportion of eyes treated with faricimab achieved IRF absence (58%-63% with Q8W, 44-49% with T&E) compared to aflibercept (36%-41%). Eyes with baseline IRF reached IRF absence a median of 40 weeks earlier with faricimab. Similarly, more eyes achieved a CST of less than 280 μm with faricimab Q8W (70-74%) versus aflibercept (61%-63%).
Reference
Lim JI, Amador MJ, Dhoot DS, et al. Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmol Retina. 2025;S2468-6530(25)00049-1. doi: 10.1016/j.oret.2025.01.017. Epub ahead of print. PMID: 39914485.
Related Content
